CARDIOVASCULAR IMPACT OF MOUNJARO IN PATIENTS WITH TYPE 2 DIABETES: CURRENT EVIDENCE AND FUTURE DIRECTIONS
DOI:
https://doi.org/10.56238/arev7n12-333Keywords:
Mounjaro, Type 2 Diabetes, Cardiovascular RiskAbstract
Type 2 diabetes (T2D) represents one of the major public health concerns, mainly due to the elevated risk of cardiovascular disease (CVD) among patients. The traditional approach focused on glycemic control, but recent studies indicate that reducing cardiovascular risk should be a priority. In this context, Mounjaro (tirzepatide), an innovative drug that combines GLP-1 and GIP receptor agonism, emerges as a promising therapy. It not only improves glycemic control but also promotes weight loss and has potential cardioprotective effects, such as improved endothelial function and reduced inflammation. Clinical evidence from phase 2 and 3 studies shows that Mounjaro significantly reduces HbA1c and postprandial glucose levels, in addition to promoting weight loss, an important factor in cardiovascular control. Cardiovascular trials such as SURPASS-CVOT indicate that tirrizepatide has a favorable cardiovascular safety profile, without increasing the risk of major cardiovascular adverse events, and suggests additional benefits such as reduced hospitalizations for heart failure and a positive impact on renal and inflammatory markers. Although clinical data show promising results, the therapy faces challenges such as gastrointestinal side effects and high cost, which may limit its use. However, Mounjaro positions itself as a robust therapeutic option that can be integrated into the treatment of T2D with high cardiovascular risk. Future research on combination therapies and treatment personalization is essential to optimize its benefits.
Downloads
References
ALHARBI SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024 DOI: https://doi.org/10.1177/20420188231222367
BODNARUC, A.M. et al. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond) 13, 92 (2016). DOI: https://doi.org/10.1186/s12986-016-0153-3
CATURANO A, et al. Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes: From Pathophysiology to Lifestyle Modifications. Antioxidants (Basel). 2025 Jan 9;14(1):72. DOI: https://doi.org/10.3390/antiox14010072
COSTA, A. F. et al. Carga do diabetes mellitus tipo 2 no Brasil. Cadernos de Saúde Pública, v. 33, n. 2, p. e00197915, 2017. DOI: https://doi.org/10.1590/0102-311x00197915
DANIEL J. DRUCKER; Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care 21 October 2024; 47 (11): 1873–1888 DOI: https://doi.org/10.2337/dci24-0003
FERRARESI, ÉRIKA L. Potencial terapêutico da tirzepatida: uma análise do estudo SURPASS-1 para o controle da obesidade e saúde metabólica. Brazilian Journal of Health Review, [S. l.], v. 8, n. 1, p. e76790, 2025. DOI: https://doi.org/10.34119/bjhrv8n1-172
GAETANO SANTULLI et al. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart. Volume 80, Issue 9, September 2023; Pages 1800-1809 DOI: https://doi.org/10.1161/HYPERTENSIONAHA.123.20598
GIOVANINI, A.B. et al. Riscos e benefícios do uso da semaglutida e tirzepatida na redução de peso corporal. Revista Amazônica de Ciências Médicas e Saúde, Ji-Paraná – RO, v. 2, n. 1, 2025.
MANARELLI, A. C. C. et al. (2025). Tirzepatida e retatrutida: a nova era do tratamento da obesidade. CONTRIBUCIONES A LAS CIENCIAS SOCIALES, 18(6), e18771. DOI: https://doi.org/10.55905/revconv.18n.6-200
MARIANO HILDEFONSO, D. et al. (2025). Inovações no Tratamento da Diabetes Mellitus Tipo 2: Terapias Emergentes e Eficácia. Brazilian Journal of Implantology and Health Sciences, 7(3), 2062–2071. DOI: https://doi.org/10.36557/2674-8169.2025v7n3p2062-2071
MARINO, E.C. et al. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025).
MARTÍN-TIMÓN I, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. DOI: https://doi.org/10.4239/wjd.v5.i4.444
MCLELLAN, K. C. P. et al. Diabetes mellitus do tipo 2, síndrome metabólica e modificação no estilo de vida. Revista de Nutrição, v. 20, n. 5, p. 515–524, set. 2007. DOI: https://doi.org/10.1590/S1415-52732007000500007
NICHOLLS SJ, et al. SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18;393(24):2409-2420.
RAMOS, V.C.G. et al. O uso de tirzepatida no combate a obesidade: uma análise dos benefícios e efeitos adversos. Revista Interdisciplinar em Saúde, Cajazeiras, 11 (único): 500-515, 2024 DOI: https://doi.org/10.35621/23587490.v11.n1.p500-515
RODRIGUES, M. F., et al. (2023). Eficácia e segurança da tirzepatida na prevenção de fatores de risco cardiovascular em pacientes com diabetes mellitus tipo 2: uma revisão sistemática. Revista CPAQV - Centro De Pesquisas Avançadas Em Qualidade De Vida , 15(3). DOI: https://doi.org/10.36692/V15N3-56R
SANTOS, K. S. et al. (2025). Avaliação do efeito da tirzepatida na perda de peso: revisão sistemática. RBONE - Revista Brasileira De Obesidade, Nutrição E Emagrecimento, 19(120), 546-557. DOI: https://doi.org/10.29327/9786527213949.1018315
WEN X, et al. Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022 Aug 28;7(1):298. doi: 10.1038/s41392-022-01149-x. Erratum in: Signal Transduct Target Ther. 2022 Oct 21;7(1):369. DOI: https://doi.org/10.1038/s41392-022-01149-x
